Inhibition of Carsinogenesis by Seed and Soybean Meal Extract in Colon of Mice: Apoptosis and Dysplasia

Abstract

Objective: Colon cancer is a major public health problem. Soybean has demonstrated chemopreventive and anticancer. Here, we have investigated the effect of a standardized seed and soybean meal extract (SE) with content of lunasin, here named grobogan extract (GE) and SE. They are botanical drug substance in experimental models of colon cancer in vivo. Methods:The effect of GE and SE was examined on the preneoplastic lesions (aberrant crypt foci), polyps and tumors induced by the carcinogenic agent azoxymethane (10 mg/kg) and dextran sodium sulfate 2% as well as in a xenograft model of colon cancer in mice.Results: GE and SE increased apoptosis (p=0.001). GE (150 mg/kg) has the highest impact level of apoptosis (p=0.009). GE and SE decreased dysplasia (p=0.024). GE (200 mg/kg) has the highest impact level of dysplasia (p=0.002), and SE (200 mg/kg) has the second impact level of dysplasia (p=0.003).Conclusions: GE and SE inhibition of colon carcinogenesis with increased level of apoptosis and decrease level of dysplasia.

The potential of lunasin extract for the prevention of breast cancer progression by upregulating E-Cadherin and inhibiting ICAM-1

“…], have been explored, as it is cheap, easy to grow, and abundant in nature. 12 Soy products are also known to lower the incidence and mortality of breast cancer, prostate cancer, colon cancer, and lung cancer. [13][14][15] The molecule in soybeans that works as an anti-cancer is considered to be a bioactive peptide called lunasin.…”

“…19 Although Lunasin Extract (LE) from the Grobogan type has been shown to have anti-inflammatory and anti-cancerous effects in the colon, studies into various anti-cancer pathways of LE are required to better understand its molecular effect on breast cancer. 12 As such, this study aims to investigate the anti-cancer effects of LE from the Grobogan variety in Indonesia. We hypothesized that LE administration could suppress breast cancer progression by decreasing ICAM-1 expression while increasing E-Cadherin expression.…”